Loading...

InnoCare Pharma Limited

9969.HK•HKSE
Healthcare
Biotechnology
HK$15.96
HK$2.12(15.32%)

InnoCare Pharma Limited (9969.HK) Stock Overview

Explore InnoCare Pharma Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 65.7/100

Key Financials

Market Cap25B
P/E Ratio-52.87
EPS (TTM)$-0.29
ROE-0.06%
Fundamental Analysis

AI Price Forecasts

1 Week$11.85
1 Month$11.92
3 Months$11.12
1 Year Target$3.01

9969.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of InnoCare Pharma Limited (9969.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 73.81, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $3.01.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -52.87 and a market capitalization of 25B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

73.81RSI (14)
0.62MACD
37.25ADX
Revenue Growth
36.68%
↑ 36.68%
Profit Growth
HK$-0.28
↑ 30.20%
EPS Growth
HK$-0.28
↑ 29.73%
Operating Margin
-1.60%
↑ 18.36%
ROE
-6.42%
↑ 30.20%
Dividend Yield
0.00%
↓ 100.00%
Analyst Recommendations data is not available for 9969.HKAnalyst Recommendations details for 9969.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.

CEO

Jisong Cui

Employees

1,089

Headquarters

Building 8, Beijing

Founded

2020

Frequently Asked Questions

;